MA-ALAKA’I-TECHNOLOGIES
29.5.2019 23:02:12 CEST | Business Wire | Press release
Today, Alaka’i Technologies unveiled Skai, the world’s first hydrogen fuel cell powered air mobility solution designed to transform the way the world moves. From its sleek, uncluttered design, radically simple and safe electric vertical takeoff and landing (eVTOL) vehicle, to its fuel source - a system that runs entirely on hydrogen fuel cells - Skai is poised to be one of the safest, cleanest and most versatile air mobility solutions introduced to the world.
Skai’s core team members are nationally-recognized aerospace experts, engineers, and veteran pilots who have served in top-level positions at NASA, Raytheon, Beech, Cirrus, DayJet, and the Department of Defense who collaborated on the vision of solving some of the world’s most-pressing global challenges across transportation, energy and the environment. Skai is co-designed by Designworks, the design innovation studio for the BMW Group, to leverage its creative expertise to help shape a world-class vehicle. The result is Skai, stripped away of all unnecessary complexity, waste and possible points of failure, leaving the most essential elements for the craft and optimizing them for the most intuitive experience.
“This remarkably impressive team have come together to build on our collective experience to finally realize our singular, critical vision to launch Skai and transform transportation,” said Brian Morrison, Co-Founder, President and Chief Technology Officer of Alaka’i Technologies. “Skai offers practical, real-life solutions to everything from relieving traffic congestion to delivering supplies during natural disasters. Skai is set to offer affordable, realistic applications in the commercial, private, freight, and personal air mobility markets.”
The heart of Skai, and one of its most revolutionary features, is the use of hydrogen fuel cells, a clean environmental solution from end to end. With the advantage of being 95% reusable and the remaining (99%) recyclable, Skai’s hydrogen fuel cells offer reliable, safe and environmentally clean emission comprised solely of heat and water. This is a stark alternative to traditional fuel and battery sources. Hydrogen fuel cells allow Skai to travel further distances and carry a greater payload.
“Air mobility is a very exciting and fascinating topic,” said Holger Hampf, President of Designworks. “Our focus for this project was to help build a new consumer facing brand from scratch - considering and designing all touchpoints - digital, physical and service. And as a result, delivering an all-encompassing user-centric experience which is purposeful and highly desirable in all aspects.”
Alaka’i Technologies has initiated their test program with the FAA. Pending certification, Skai will create new possibilities in personal mobility for everyone, efficient emergency responses, economical freight distribution, and the utilization of hydrogen fuel cells as a highly reliable, zero-emission power source.
Skai Highlights Include:
- Co-designed by Designworks with inherent quality craftsmanship
- Powered by clean hydrogen fuel cells, with zero emissions
- Range: Up to 4 Hours, ~400 Miles
- Six reliable, quiet, efficient electric motors with designed-in redundancy
- Seats up to five passengers
- Reliable, fault-tolerant architecture for safety and security
- Piloted version launched first, with autonomous versions to follow
- Designed for the ultimate in safety, with an Airframe Parachute
For more information: http://skai.co .
ABOUT ALAKA’I
Alaka’i Technologies is an emerging air mobility design and manufacturing company, headquartered in Hopkinton MA. Founded by Brian Morrison in 2015, Alaka’i Technologies assembled a distinguished executive team with decades of aerospace development, production, executive and airspace integration experience (NASA, Raytheon, Beech Aircraft, McDonnell Douglas, Hughes, DayJet, SATSAir, Cirrus, Metro Aviation, Delta Airlines) and FAA certification experience. Working together since the 1990’s on industry-defining projects such as the NASA AGATE and SATS Programs, they also built and flew the world’s first-ever Fly-By-Light aircraft. Today, the Alaka'i team is engineering proprietary, progressive air mobility solutions to offer point A-to-Anywhere transportation that are clean, simple, safe, and accessible for everyone. Ultimately, transforming transportation through hydrogen-powered mobility.
ABOUT DESIGNWORKS
Designworks is the design innovation studio for the BMW Group. Designworks is ‘the architect of future’ — designing holistic systems that impact and improve the world we live in. Designworks inspires and challenges the companies it works with to be and stay at the forefront of their industries in design, technology and innovation. For 25 years it has been stimulating the BMW Group as well as a select group of companies with ambitious visions for the future.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190529005834/en/
Contact:
John Moore Press@alakai.com
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
The Estée Lauder Companies Appoints Madeleine Boyd as Senior Vice President, Global Brand Communications16.7.2026 22:22:00 CEST | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced the appointment of Madeleine Boyd as Senior Vice President, Global Brand Communications, effective July 20, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716738393/en/ Photo by Esteban La Tessa As part of the company’s continued efforts to strengthen how its brands better connect with consumers, Ms. Boyd will establish and lead a newly integrated Global Brand Communications team. In this role, she will ensure the company’s diverse portfolio is anchored by a cohesive enterprise communications strategy, while accelerating bold, consumer-first storytelling that drives earned media, cultural relevance, and brand desirability. She will also strengthen creator engagement, helping the company’s brands gain attention where culture is being shaped. Ms. Boyd brings extensive experience spanning brand strategy, communications, consumer engagement, and cultural insight
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
